Copyright
©The Author(s) 2017.
World J Gastrointest Oncol. Mar 15, 2017; 9(3): 121-128
Published online Mar 15, 2017. doi: 10.4251/wjgo.v9.i3.121
Published online Mar 15, 2017. doi: 10.4251/wjgo.v9.i3.121
Table 3 First-line chemotherapy regime
| Chemotherapy regime (n = 171) | n (%) |
| Anthracycline + platinum-based agent + nucleotide analogue Examples epirubicin + cisplatin + 5-fluorouracil epirubicin + oxaliplatin + 5-fluorouracil | 13 (7.6) |
| Platinum-based agent + nucleotide analogue Examples cisplatin + 5-fluorouracil oxaliplatin + capecitabine cisplatin + S-1 | 97 (56.7) |
| Nucleotide analogue monotherapy Examples 5-fluorouracil capecitabine S-1 | 30 (17.5) |
| FOLFOX (5-fluorouracil + leucovorin + oxaliplatin) | 24 (14.0) |
| Other regimes (e.g., Docetaxel + cisplatin + 5-fluorouracil) | 7 (4.2) |
- Citation: Tan HL, Chia CS, Tan GHC, Choo SP, Tai DWM, Chua CWL, Ng MCH, Soo KC, Teo MCC. Gastric peritoneal carcinomatosis - a retrospective review. World J Gastrointest Oncol 2017; 9(3): 121-128
- URL: https://www.wjgnet.com/1948-5204/full/v9/i3/121.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v9.i3.121